-
Tytuł:
-
[Clinical Analysis of 37 Patients with Primary Tonsil Diffuse Large B Cell Lymphoma].
-
Autorzy:
-
Tian T; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Wang L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Zhu HY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Liang JH; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Wu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Cao L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Fan L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Li JY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China.
Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) , Nanjing 210029, Jiangsu province, China,E-mail: .
-
Źródło:
-
Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2019 Apr; Vol. 27 (2), pp. 426-432.
-
Typ publikacji:
-
Journal Article
-
Język:
-
Chinese
-
Imprint Name(s):
-
Original Publication: Beijing : Zhongguo shi yan xue za zhi she,
-
MeSH Terms:
-
Lymphoma, Large B-Cell, Diffuse*
Palatine Tonsil*
Tonsillar Neoplasms*
Aged ; Humans ; Middle Aged ; Prognosis
-
Contributed Indexing:
-
Local Abstract: [Publisher, Chinese] 原发扁桃体弥漫大B细胞淋巴瘤37例临床分析. [Publisher, Chinese] 总结原发扁桃体弥漫大B细胞淋巴瘤(PT-DLBCL)的临床特征、免疫表型及预后因素. [Publisher, Chinese] 收集2009年10月至2018年2月初诊的37例PT-DLBCL患者临床资料,包括临床特征、分型、分期、疗效及预后,并进行回顾性分析. [Publisher, Chinese] 37例中男性22例(59.5%),女性15例(40.5%),中位年龄57(16-86)岁。能明确细胞起源的36例患者中,生发中心B细胞(GCB)型占66.7%,非生发中心B细胞(non-GCB)型占33.3%。Ann Arbor分期Ⅰ期占40.5 %,Ⅱ期占59.5%,无Ⅲ、Ⅳ期患者。中位随访时间44(10-101)月,2例患者(5.4%)失访。中位治疗6(3-8)个疗程后对35例患者进行评估。结果显示,26例(74.3%)达完全缓解(CR),8例(22.9%)达部分缓解(PR),1例(2.8%)患者疾病稳定(SD)。3年及5年无进展生存(PFS)均为82.5%,3年及5年总生存(OS)均为95.5%。5例(13.5%)患者接受了放疗。年龄>60岁(P<0.05)或年龄>70岁(P<0.05)的患者PFS均较相对年轻患者短;LDH水平增高(P<0.001)、治疗方案中未使用R(P<0.05)的患者OS相对短. [Publisher, Chinese] PT-DLBCL患者对放、化疗敏感,预后较好,大多数患者治疗后可获得长期生存,联合免疫化疗的效果优于单纯化疗.
-
Entry Date(s):
-
Date Created: 20190419 Date Completed: 20190430 Latest Revision: 20190430
-
Update Code:
-
20240104
-
DOI:
-
10.19746/j.cnki.issn.1009-2137.2019.02.019
-
PMID:
-
30998149
-
Objective: To investigate the clinical manifestation, immunophenotypes and prognostic factors of patients with primary tonsil afftive large B cell lymphoma ( PT-DLBCL ).
Methods: The clinical data including clinical characterstics, typing, staging, treatment efficacy and prognostic factors of PT-DLBCL patients were collected and analyzed restrospectively.
Results: Out of 36 cases with the detinite cell origin, 24 cases (66.7%) were detecmined as the type of germinal center B-cell (GCB) and 12 cases (33.3%) was non-germinal center B-cell (non-GCB), 15 (40.5%) out of 37 cases were in Ann Arbor stage Ⅰ, and 22 (59.5%) in stage Ⅱ. With the median follow-up of 44 (10-101) months, 2 cases (5.4%) failed to be followed-up, after treatment for 6 (3-8) cycles 35 patients were evaluated. Among them 26 cases (74.3%) reached to complete remission (CR), 8 cases (22.9%) to partial remission ( PR ), and 1 (2.8%) to stable disease (SD). Both the 3 years and 5 years progression-free survival ( PFS ) were 82.5%, and both 3 and 5 years overall survival (OS) were 95.5%. 5 cases (13.5%) received radiotherapy. The patients aged>60 ( P<0.05 ) or aged>70 (P<0.05) had shorter PFS than younger patients. The patients with increased lactic dehydrogenase ( LDH ) level (P<0.01) and without rituximab (R) (P<0.05) in the treatment regimen had relatively short OS.
Conclusion: The patients sensitive to chemotherapy and/or radiotherapy have a good prognosis. Most of the patients can obtain long-term survival after treatment. The effect of combined immunotherapy are better than that of the simple chemotherapy.